Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL-SIMPLIFIED: Tenecteplase for Acute Ischemic Stroke in the Extended Time Window
NCT07606807Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ischemic stroke (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Excellent functional outcome (modified Rankin Scale score 0-1) at 90 days. Started Aug 2026; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07606807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07606807.